Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective
- PMID: 30377941
- DOI: 10.1007/s12094-018-1967-4
Optimization of surgical treatment of advanced ovarian cancer: a Spanish expert perspective
Abstract
Background: Optimal upfront treatment of patients with advanced ovarian cancer is complex and requires the adequate function of a multidisciplinary team. Specific standard of quality of care needs to be taken into consideration.
Methods: A literature search in PubMed was performed using the following criteria: ("ovarian neoplasms"[MeSH Terms] OR ("ovarian"[All Fields] AND "neoplasms"[All Fields]) OR "ovarian neoplasms"[All Fields] OR ("ovarian"[All Fields] AND "cancer"[All Fields]) OR "ovarian cancer"[All Fields])"[Date - Publication]: "2018/01/14"[Date - Publication]).
Results: This article describes how to optimize the surgical management of advanced ovarian cancer, to achieve the best results in terms of survival and quality of life. For this purpose, this document will cover aspects related to pre-, intra- and postoperative care of newly diagnosed advanced ovarian cancer patients.
Conclusion: Optimizing upfront treatment of patients with advanced ovarian cancer is complex and requires a structured quality management program including the wise judgment of a multidisciplinary team. Surgeries performed by gynecologic oncologists with formal training in cytoreductive techniques at referral centers are crucial factors to obtain better clinical and oncological outcomes. However, other factors such as the patient's clinical status, the hospital infrastructure and equipment, as well as the tumor biology of each individual patient should also be taken into account before deciding on an initial therapeutic strategy for advanced-stage ovarian cancer to offer patients the best quality of care.
Keywords: Advanced stage; Optimization of treatment; Ovarian cancer; Peritoneal carcinomatosis; Quality of care.
Similar articles
-
Primary surgical cytoreduction in advanced ovarian cancer: An outcome analysis within the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group.Gynecol Oncol. 2016 Mar;140(3):425-9. doi: 10.1016/j.ygyno.2016.01.025. Epub 2016 Jan 26. Gynecol Oncol. 2016. PMID: 26825616
-
Current status of ovarian cancer surgical management. Argument for centralisation of care in Australia.Aust N Z J Obstet Gynaecol. 2018 Aug;58(4):474-477. doi: 10.1111/ajo.12832. Epub 2018 May 31. Aust N Z J Obstet Gynaecol. 2018. PMID: 29851066
-
Surgical program building in advanced ovarian cancer: European perspective.Gynecol Oncol. 2009 Aug;114(2 Suppl):S10-4. doi: 10.1016/j.ygyno.2008.11.019. Gynecol Oncol. 2009. PMID: 19573699
-
Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.Curr Treat Options Oncol. 2016 Jan;17(1):1. doi: 10.1007/s11864-015-0380-2. Curr Treat Options Oncol. 2016. PMID: 26714493 Review.
-
Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: Time to incorporate laparoscopic assessment into the standard of care.Gynecol Oncol. 2015 Jun;137(3):553-8. doi: 10.1016/j.ygyno.2015.03.049. Epub 2015 Mar 28. Gynecol Oncol. 2015. PMID: 25827290 Free PMC article. Review.
Cited by
-
Ovarian cancer and its management through advanced drug delivery system.Med Oncol. 2025 Feb 17;42(3):76. doi: 10.1007/s12032-025-02621-8. Med Oncol. 2025. PMID: 39960609 Review.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical